AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
Latest, Q2 2026
3,601
Period ended Jun 30, 2026
Change on a year earlier
+288.0%
928 in Q2 2025
History
58 quarters
Since Q1 2012
Sources
51
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Net earnings attributable to AbbVie Inc. ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 3,601 | +288.0% | Form 10-Q (filed 2026-08-03) ↗ |
| Q1 2026 | Mar 31, 2026 | 685 | -46.3% | Form 10-Q (filed 2026-05-08) ↗ |
| Q4 2025 | Dec 31, 2025 | 1,806 | -5,743.7% | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2025 | Sep 30, 2025 | 176 | -88.7% | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2025 | Jun 30, 2025 | 928 | -31.8% | Form 10-Q (filed 2025-08-04) ↗ |
| Q1 2025 | Mar 31, 2025 | 1,276 | -6.1% | Form 10-Q (filed 2025-05-09) ↗ |
| Q4 2024 | Dec 31, 2024 | -32 | -103.9% | Form 10-K (filed 2025-02-14) ↗ |
| Q3 2024 | Sep 30, 2024 | 1,551 | -12.2% | Form 10-Q (filed 2024-11-04) ↗ |
| Q2 2024 | Jun 30, 2024 | 1,360 | -32.4% | Form 10-Q (filed 2024-08-07) ↗ |
| Q1 2024 | Mar 31, 2024 | 1,359 | +496.1% | Form 10-Q (filed 2024-05-03) ↗ |
| Q4 2023 | Dec 31, 2023 | 811 | -67.1% | Form 10-K (filed 2024-02-20) ↗ |
| Q3 2023 | Sep 30, 2023 | 1,767 | -55.0% | Form 10-Q (filed 2023-11-06) ↗ |
| Q2 2023 | Jun 30, 2023 | 2,013 | +120.5% | Form 10-Q (filed 2023-08-07) ↗ |
| Q1 2023 | Mar 31, 2023 | 228 | -94.9% | Form 10-Q (filed 2023-05-05) ↗ |
| Q4 2022 | Dec 31, 2022 | 2,462 | -38.8% | Form 10-K (filed 2023-02-17) ↗ |
| Q3 2022 | Sep 30, 2022 | 3,931 | +24.5% | Form 10-Q (filed 2022-11-04) ↗ |
| Q2 2022 | Jun 30, 2022 | 913 | +21.9% | Form 10-Q (filed 2022-08-04) ↗ |
| Q1 2022 | Mar 31, 2022 | 4,468 | +26.6% | Form 10-Q (filed 2022-05-06) ↗ |
| Q4 2021 | Dec 31, 2021 | 4,023 | +20,015.0% | Form 10-K (filed 2022-02-18) ↗ |
| Q3 2021 | Sep 30, 2021 | 3,158 | +37.8% | Form 10-Q (filed 2021-11-02) ↗ |
| Q2 2021 | Jun 30, 2021 | 749 | -199.1% | Form 10-Q (filed 2021-08-02) ↗ |
| Q1 2021 | Mar 31, 2021 | 3,529 | +17.8% | Form 10-Q (filed 2021-05-07) ↗ |
| Q4 2020 | Dec 31, 2020 | 20 | -99.3% | Form 10-K (filed 2021-02-19) ↗ |
| Q3 2020 | Sep 30, 2020 | 2,291 | +22.3% | Form 10-Q (filed 2020-11-04) ↗ |
| Q2 2020 | Jun 30, 2020 | -756 | -203.1% | Form 10-Q (filed 2020-08-04) ↗ |
| Q1 2020 | Mar 31, 2020 | 2,996 | +22.6% | Form 10-Q (filed 2020-05-08) ↗ |
| Q4 2019 | Dec 31, 2019 | 2,788 | -253.0% | Form 10-K (filed 2020-02-21) ↗ |
| Q3 2019 | Sep 30, 2019 | 1,874 | -31.5% | Form 10-Q (filed 2019-11-06) ↗ |
| Q2 2019 | Jun 30, 2019 | 733 | -62.8% | Form 10-Q (filed 2019-08-05) ↗ |
| Q1 2019 | Mar 31, 2019 | 2,444 | -11.8% | Form 10-Q (filed 2019-05-03) ↗ |
| Q4 2018 | Dec 31, 2018 | -1,822 | -3,603.8% | Form 10-K (filed 2019-02-27) ↗ |
| Q3 2018 | Sep 30, 2018 | 2,735 | +68.5% | Form 10-Q (filed 2018-11-07) ↗ |
| Q2 2018 | Jun 30, 2018 | 1,973 | +3.5% | Form 10-Q (filed 2018-08-07) ↗ |
| Q1 2018 | Mar 31, 2018 | 2,771 | +62.8% | Form 10-Q (filed 2018-05-04) ↗ |
| Q4 2017 | Dec 31, 2017 | 52 | -96.2% | Form 10-K (filed 2018-02-16) ↗ |
| Q3 2017 | Sep 30, 2017 | 1,623 | +2.1% | Form 10-Q (filed 2017-11-07) ↗ |
| Q2 2017 | Jun 30, 2017 | 1,906 | +19.0% | Form 10-Q (filed 2017-08-07) ↗ |
| Q1 2017 | Mar 31, 2017 | 1,702 | +26.4% | Form 10-Q (filed 2017-05-05) ↗ |
| Q4 2016 | Dec 31, 2016 | 1,384 | -8.8% | Form 10-K (filed 2017-02-17) ↗ |
| Q3 2016 | Sep 30, 2016 | 1,590 | +29.1% | Form 10-Q (filed 2016-11-07) ↗ |
| Q2 2016 | Jun 30, 2016 | 1,602 | +17.3% | Form 10-Q (filed 2017-08-07) ↗ |
| Q1 2016 | Mar 31, 2016 | 1,347 | +31.8% | Form 10-Q (filed 2017-05-05) ↗ |
| Q4 2015 | Dec 31, 2015 | 1,517 | -287.3% | Form 10-K (filed 2016-02-19) ↗ |
| Q3 2015 | Sep 30, 2015 | 1,232 | +143.5% | Form 10-Q (filed 2016-11-07) ↗ |
| Q2 2015 | Jun 30, 2015 | 1,366 | +24.4% | Form 10-Q (filed 2015-08-07) ↗ |
| Q1 2015 | Mar 31, 2015 | 1,022 | +4.3% | Form 10-Q (filed 2015-05-08) ↗ |
| Q4 2014 | Dec 31, 2014 | -810 | -171.8% | Form 10-K (filed 2015-02-20) ↗ |
| Q3 2014 | Sep 30, 2014 | 506 | -47.5% | Form 10-Q (filed 2014-11-07) ↗ |
| Q2 2014 | Jun 30, 2014 | 1,098 | +2.8% | Form 10-Q (filed 2014-08-07) ↗ |
| Q1 2014 | Mar 31, 2014 | 980 | +1.2% | Form 10-Q (filed 2014-05-09) ↗ |
| Q4 2013 | Dec 31, 2013 | 1,128 | -26.8% | Form 10-K (filed 2014-02-21) ↗ |
| Q3 2013 | Sep 30, 2013 | 964 | -39.2% | Form 10-Q (filed 2013-11-12) ↗ |
| Q2 2013 | Jun 30, 2013 | 1,068 | -15.7% | Form 10-Q (filed 2013-08-09) ↗ |
| Q1 2013 | Mar 31, 2013 | 968 | +9.6% | Form 10-Q (filed 2013-05-08) ↗ |
| Q4 2012 | Dec 31, 2012 | 1,540 | – | Form 10-K (filed 2014-02-21) ↗ |
| Q3 2012 | Sep 30, 2012 | 1,585 | – | Form 10-Q (filed 2013-11-12) ↗ |
| Q2 2012 | Jun 30, 2012 | 1,267 | – | Form 10-Q (filed 2013-08-09) ↗ |
| Q1 2012 | Mar 31, 2012 | 883 | – | Form 10-Q (filed 2013-05-08) ↗ |
Cite this data
StockData. (2026). AbbVie Net earnings attributable to AbbVie Inc. ($M) ($M), quarterly Q1 2012–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/fs_ni
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.